Resmetirom

Resmetirom (MGL-3196) is a first-in-class, orally administered, liver-directed thyroid hormone receptor-β (THR-β) agonist. It is under advanced clinical development for the treatment of nonalcoholic steatohepatitis (NASH) and dyslipidemia. By selectively targeting liver metabolism, Resmetirom helps reduce liver fat, cholesterol levels, and fibrosis without systemic thyroid-related side effects.

Our high-purity Resmetirom API is produced under strict quality control standards and is suitable for pharmaceutical research, formulation development, and commercial drug manufacturing.

Applications:

• Treatment of NASH (Non-Alcoholic Steatohepatitis)

• Thyroid hormone receptor modulator in drug development

• Used in clinical and pharmaceutical R&D

Packaging:
Available in 1g, 10g, 100g, 1kg foil bags or custom packaging

Storage:
Store in a cool, dry place away from light and moisture. Recommended storage temperature: 2–8°C